View Older Stories

May 5, 2026 10:20AM Spyre Therapeutics, Inc. (SYRE) Misses Q1 EPS by 7c

Apr 13, 2026 04:21PM Raymond James Starts Spyre (SYRE) at Strong Buy, $80 PT

Apr 13, 2026 03:10PM Spyre (SYRE) PT Raised to $84 at Mizuho

Apr 13, 2026 02:39PM Syre Therapeutics (SYPR) PT Raised to $106 at Leerink Partners, 'initial SKYLINE results represent best-case data for SPY001'

Apr 13, 2026 12:37PM Spyre (SYRE) PT Raised to $85 at Jefferies

Apr 13, 2026 11:24AM Spyre (SYRE) PT Raised to $98 at BTIG

Apr 13, 2026 10:38AM Spyre (SYRE) PT Raised to $80 at Wedbush

Apr 13, 2026 08:45AM Stifel on Spyre (SYRE): 'solid foundation for combos where we expect synergistic activity'

Apr 13, 2026 08:26AM Goldman Sachs on Spyre (SYRE): 'Initial SPY001 efficacy data bolsters confidence into remaining data readouts later this year'

Apr 13, 2026 08:21AM Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'

Apr 13, 2026 07:57AM TD Cowen on Spyre (SYRE): 'we expect these data to further raise the ceiling for Spyre's future combos'

Apr 13, 2026 07:54AM Mizuho on Spyre (SYRE): 'We see these results as an extremely favorable outcome'

Apr 13, 2026 07:46AM Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news'

Apr 13, 2026 07:00AM Spyre reports positive trial results for ulcerative colitis drug SPY001

Apr 13, 2026 06:56AM Spyre Therapeutics (SYRE) Halted, News Pending

Mar 31, 2026 05:18AM BTIG Reiterates Buy Rating on Spyre (SYRE)

Mar 18, 2026 07:32AM Spyre (SYRE) PT Raised to $92 at Stifel

Mar 16, 2026 11:33AM Leerink Partners Reiterates Outperform Rating on Spyre (SYRE): 'today's update reflects SYRE's strong clinical execution'

Mar 16, 2026 10:39AM Guggenheim on Spyre Therapeutics (SYRE): 'remains one of our Top 2026 Picks'

Feb 19, 2026 04:35PM Spyre Therapeutics (SYRE) files mixed shelf

Jan 12, 2026 08:04AM Spyre Therapeutics expects six trial readouts in 2026

Dec 17, 2025 04:04PM Mizuho Starts Spyre (SYRE) at Outperform

Dec 17, 2025 05:02AM Citi Starts Spyre (SYRE) at Buy

Dec 1, 2025 12:33AM Jones Trading Upgrades Spyre (SYRE) to Buy

Nov 5, 2025 07:29AM Spyre (SYRE) PT Lowered to $70 at Stifel

Nov 4, 2025 05:50PM Spyre Therapeutics, Inc. (SYRE) Tops Q3 EPS by 62c

Oct 13, 2025 04:41PM Spyre Therapeutics (SYRE) seeking $200M in share sale at $18.50/sh - Bloomberg

Oct 7, 2025 05:55AM Guggenheim Reiterates Buy Rating on Spyre (SYRE), 'remains one of our Top Picks'

Sep 26, 2025 03:27AM Deutsche Bank Starts Spyre (SYRE) at Buy

Aug 18, 2025 06:13AM Guggenheim Reiterates Buy Rating on Spyre (SYRE)

Aug 6, 2025 03:16AM Stifel Reiterates Buy Rating on Spyre (SYRE)

Jun 17, 2025 07:30AM Spyre Therapeutics (SYRE) Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs

Jun 4, 2025 06:23AM Leerink Partners Reiterates Outperform Rating on Spyre (SYRE)

Jun 3, 2025 06:20AM Guggenheim Reiterates Spyre (SYRE) at Buy, 'optimistic that the company is best-positioned to pioneer longer-acting mAb therapeutics in IBD'

May 8, 2025 04:17PM Spyre Therapeutics, Inc. (SYRE) Tops Q1 EPS by 24c

Mar 28, 2025 05:24AM BTIG Reiterates Buy Rating on Spyre (SYRE)

Mar 18, 2025 04:37AM Wolfe Research Starts Spyre (SYRE) at Outperform

Mar 7, 2025 04:43PM Spyre Therapeutics (SYRE) approves inducement awards to non-exec employees

Feb 27, 2025 04:34PM Spyre Therapeutics (SYRE) Files Mixed Shelf

Feb 27, 2025 04:17PM Spyre Therapeutics, Inc. (SYRE) Tops Q4 EPS by 22c

Dec 3, 2024 06:36AM Baird Reiterates Outperform Rating on Spyre (SYRE)

Dec 2, 2024 08:10AM Spyre Therapeutics (SYRE) Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Nov 18, 2024 04:14PM Spyre Therapeutics (SYRE) Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Nov 12, 2024 12:50PM Spyre (SYRE) PT Raised to $71 at Stifel

Nov 12, 2024 07:30AM Spyre Therapeutics (SYRE) Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001

Nov 7, 2024 04:21PM Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 54c

Oct 25, 2024 06:08AM Spyre (SYRE) PT Raised to $65 at Guggenheim

Oct 17, 2024 06:50AM Baird Reiterates Outperform Rating on Spyre (SYRE)

Oct 15, 2024 06:18AM Wells Fargo Reiterates Overweight Rating on Spyre (SYRE)

Oct 15, 2024 05:58AM BTIG Reiterates Buy Rating on Spyre (SYRE)

View Older Stories